InvestSMART

Bioxyne Limited (ASX: BXN) - Announcements

Current share price for BXN : $0.930 0.01 (1.06%)+

ASX company news and announcements for Bioxyne Limited (BXN) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Bioxyne Limited (BXN) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Bioxyne Limited (BXN), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Bioxyne Limited (BXN)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$214 Application for quotation of securities - BXN 20 Mar 2026 6:06PM $0.051 $0.930 risen by 1,723.53%
$214 Application for quotation of securities - BXN 18 Mar 2026 6:12PM $0.050 $0.930 risen by 1,760%
$214 BXN H1 FY2026 Results Presentation 26 Feb 2026 10:14AM $0.058 $0.930 risen by 1,503.45%
$214 Stronger H1 FY2026 Performance Upward Revision to Guidance 26 Feb 2026 9:50AM $0.052 $0.930 risen by 1,688.46%
$214 Half Yearly Report and Accounts 26 Feb 2026 9:46AM $0.052 $0.930 risen by 1,688.46%
$214 Bioxyne Webinar Half Year Results Review 26 Feb 11am AEDT 13 Feb 2026 10:22AM $0.046 $0.930 risen by 1,921.74%
$214 BXN Commercialises GMP-Manufactured Psilocybin Capsules 11 Feb 2026 8:18AM $0.045 $0.930 risen by 1,966.67%
$214 Application for quotation of securities - BXN 30 Jan 2026 5:57PM $0.039 $0.930 risen by 2,284.62%
$214 Details of Auditor Appointment/Resignation 30 Jan 2026 12:17PM $0.040 $0.930 risen by 2,254.43%
$214 Presentation Results Q2 FY2026 29 Jan 2026 11:06AM $0.039 $0.930 risen by 2,284.62%
$214 Appendix 4C Revised 28 Jan 2026 8:35AM $0.042 $0.930 risen by 2,114.29%
$214 Quarterly Activities/Appendix 4C Cash Flow Report 28 Jan 2026 8:21AM $0.042 $0.930 risen by 2,114.29%
$214 Appendix 3H 16 Jan 2026 8:28PM $0.040 $0.930 risen by 2,225%
$214 Change of Directors Interest Notice X 2 24 Dec 2025 10:18AM $0.042 $0.930 risen by 2,114.29%
$214 Notification regarding unquoted securities - BXN 24 Dec 2025 10:14AM $0.042 $0.930 risen by 2,114.29%
$214 Application for quotation of securities - BXN 24 Dec 2025 10:03AM $0.042 $0.930 risen by 2,114.29%
$214 Notification regarding unquoted securities - BXN 18 Dec 2025 6:21PM $0.043 $0.930 risen by 2,062.79%
$214 Directors Change of Interest Notice X 2 15 Dec 2025 9:27AM $0.039 $0.930 risen by 2,284.62%
$214 Cleansing Notice 15 Dec 2025 9:20AM $0.039 $0.930 risen by 2,284.62%
$214 Application for quotation of securities - BXN 15 Dec 2025 9:15AM $0.039 $0.930 risen by 2,284.62%
$214 Application for quotation of securities - BXN 15 Dec 2025 9:13AM $0.039 $0.930 risen by 2,284.62%
$214 Supply Agreement Secured - Central American Cannabis Markets 11 Dec 2025 8:44AM $0.037 $0.930 risen by 2,413.51%
$214 BXN Strengthens Financial Leadership - KEY CFO Appointment 2 Dec 2025 8:36AM $0.037 $0.930 risen by 2,413.51%
$214 Results of Meeting 26 Nov 2025 4:28PM $0.037 $0.930 risen by 2,413.51%
$214 CEO Address BXN Annual General Meeting 26 Nov 2025 1:54PM $0.036 $0.930 risen by 2,483.33%

26 - 50 of 457 results

Page 2 of 19

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.